A federal outside panel voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is not final. The FDA has given no signal on whether it will move in step with the panel. The move came after weeks of public hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could reshape how the agency handles a part of the wellness market that is surging ahead. Market observers are watching to see if the regulator moves in step. A spokesperson for the regulator offered no firm timeline for a follow-up. Wellness voices argue the change would expand access to substances users swear by. Health groups warn that looser rules could weaken safeguards across a fast-moving market. The Thursday vote only plants the seed for a shift, and the final call rests with the regulator.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch